Suppr超能文献

CD105评估的微血管密度在喉癌中的预后相关性。

Prognostic relevance of CD105-assessed microvessel density in laryngeal carcinoma.

作者信息

Zvrko Elvir, Mikic Anton, Vuckovic Ljiljana, Djukic Vojko, Knezevic Milan

机构信息

Clinic for Otorhinolaryngology and Maxillofacial Surgery, Clinical Center of Montenegro, Podgorica, Montenegro.

出版信息

Otolaryngol Head Neck Surg. 2009 Oct;141(4):478-83. doi: 10.1016/j.otohns.2009.07.001.

Abstract

OBJECTIVE

To examine immunohistochemical expression of CD105 among patients with laryngeal cancer and investigate the prognostic significance of CD105-assessed microvessel density (MVD).

STUDY DESIGN

Cross-sectional study.

SETTING

University hospital.

SUBJECTS AND METHODS

The study comprised 80 patients with laryngeal squamous cell carcinoma who underwent complete excision. Clinicopathological data were collected retrospectively. Immunohistochemical analysis was performed with CD105 (endoglin) antibody. Positive-stained microvessels for CD105 were counted on hot spots of tumors at x200 magnification.

RESULTS

Average CD105-assessed MVD in considered laryngeal squamous cell carcinomas (SCCs) was 12.9 (SD 3.84). High expression of CD105 correlated significantly with advanced T (tumor) classification (P = 0.008), advanced TNM (tumor, node, metastasis) stage (P = 0.001), tumor recurrence (P = 0.001), and age > or =65 years (P = 0.026). The multivariate logistic regression showed that a high CD105+ MVD (odds ratio [OR] 4.27; P = 0.019) and advanced TNM stage (OR 3.72; P = 0.047) were independent markers of tumor recurrence. High MVD, advanced clinical stage, the presence of lymph node metastasis at the time of diagnosis, and age <66 years were associated with worse disease-free survival. Cox regression analysis revealed that expression of CD105 (P = 0.016) and advanced clinical stage (P = 0.05) were the independent factors for disease-free survival.

CONCLUSION

The present results suggest that MVD evaluation with CD105 is a promising prognostic factor for the outcome of patients with laryngeal SCC. CD105-assessed MVD could help to identify patients with more aggressive disease and increased risk of developing malignancy recurrence after treatment.

摘要

目的

检测喉癌患者中CD105的免疫组化表达,并探讨通过CD105评估的微血管密度(MVD)的预后意义。

研究设计

横断面研究。

研究地点

大学医院。

研究对象与方法

本研究纳入80例行完整切除的喉鳞状细胞癌患者。回顾性收集临床病理资料。采用CD105(内皮糖蛋白)抗体进行免疫组化分析。在200倍放大倍数下,对肿瘤热点区域中CD105阳性染色的微血管进行计数。

结果

在纳入的喉鳞状细胞癌(SCC)中,通过CD105评估的平均MVD为12.9(标准差3.84)。CD105的高表达与T(肿瘤)分期进展(P = 0.008)、TNM(肿瘤、淋巴结、转移)分期进展(P = 0.001)、肿瘤复发(P = 0.001)以及年龄≥65岁(P = 0.026)显著相关。多因素逻辑回归显示,高CD105 + MVD(比值比[OR] 4.27;P = 0.019)和TNM分期进展(OR 3.72;P = 0.047)是肿瘤复发的独立标志物。高MVD、临床分期进展、诊断时存在淋巴结转移以及年龄<66岁与无病生存期较差相关。Cox回归分析显示,CD105的表达(P = 0.016)和临床分期进展(P = 0.05)是无病生存期的独立因素。

结论

目前的结果表明,用CD105评估MVD是喉SCC患者预后的一个有前景的预测因素。通过CD105评估的MVD有助于识别疾病侵袭性更强且治疗后发生恶性肿瘤复发风险增加的患者。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验